BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/20/2022 10:47:59 AM | Browse: 364 | Download: 642
 |
Received |
|
2021-03-26 13:24 |
|
Peer-Review Started |
|
2021-03-26 13:33 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-07-18 03:07 |
|
Revised |
|
2021-08-06 16:06 |
|
Second Decision |
|
2021-12-17 03:24 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-12-23 05:43 |
|
Articles in Press |
|
2021-12-23 05:43 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-12-10 12:23 |
|
Typeset the Manuscript |
|
2022-01-06 08:30 |
|
Publish the Manuscript Online |
|
2022-01-20 10:47 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Modified mesenchymal stem cells in cancer therapy: A smart weapon requiring upgrades for wider clinical applications
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Carla Vicinanza, Elisabetta Lombardi, Francesco Da Ros, Miriam Marangon, Cristina Durante, Mario Mazzucato and Francesco Agostini |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Italian Ministry of Health “Ricerca Corrente” |
J34I19003280007 |
| Organization “Alleanza Contro il Cancro (ACC)” |
J34I20000600001 |
| Association “Finchè ci siete voi ci sono anch'io” |
J31I17000440007 |
|
| Corresponding Author |
Francesco Agostini, PhD, Senior Researcher, Senior Scientist, Stem Cell Unit, Centro di Riferimento Oncologico di Aviano, IRCCS, Via F. Gallini, 2, Aviano 33081, Italy. fagostini@cro.it |
| Key Words |
Cancer; Mesenchymal stem stromal cells; Good manufacturing practice; Homing; Targeted therapy; Ex vivo cell modification |
| Core Tip |
Natural tropism towards a tumor mass and the cytotoxic potential of mesenchymal stem stromal cells (MSC) need to be ex vivo ameliorated in order to improve clinical effectiveness of cell therapies against cancer. We review genetic engineering, membrane modification and other approaches to upgrade migration and tumor killing activity of MSC. As cell manipulation must be compliant with good manufacturing practice (GMP) guidelines, ex vivo cell modification protocols were selected as potentially compatible with GMP regulations, after appropriate protocol design and validation. Modified cell products must be tested for their clinical relevance in cancer patients within highly standardized clinical trials. |
| Publish Date |
2022-01-20 10:47 |
| Citation |
Vicinanza C, Lombardi E, Da Ros F, Marangon M, Durante C, Mazzucato M, Agostini F. Modified mesenchymal stem cells in cancer therapy: A smart weapon requiring upgrades for wider clinical applications. World J Stem Cells 2022; 14(1): 54-75 |
| URL |
https://www.wjgnet.com/1948-0210/full/v14/i1/54.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v14.i1.54 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
